Patents Assigned to HOSPICES CIVIL DE LYON
-
Patent number: 9120856Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.Type: GrantFiled: July 18, 2011Date of Patent: September 1, 2015Assignees: INTERNATIONAL-DRUG-DEVELOPMENT BIOTECH, UCBL UNIVERSITE CLAUDE BERNARD DE LYON 1, HOSPICES CIVILS DE LYONInventors: Gilles Salles, Claudine Vermot-Desroches
-
Patent number: 9110079Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.Type: GrantFiled: September 23, 2011Date of Patent: August 18, 2015Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON (HCL)Inventors: Marie-Angélique Cazalis, Alexandre Pachot, Sylvie Tissot, Guillaume Monneret
-
Publication number: 20150064728Abstract: The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.Type: ApplicationFiled: March 22, 2013Publication date: March 5, 2015Applicants: HOSPICES CIVILS DE LYON, BIOMERIEUXInventors: Alain Lepape, Fabienne Venet, Astrid Villars, Guillaume Monneret
-
Patent number: 8956626Abstract: Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins.Type: GrantFiled: July 8, 2011Date of Patent: February 17, 2015Assignees: Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre National de la Recherche Scientifique (CNRS)Inventors: Vincent Moules, Manuel Rosa-Calatrava, Olivier Ferraris, Matthieu Yver
-
Patent number: 8926988Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: January 6, 2015Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Patent number: 8927701Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.Type: GrantFiled: July 18, 2008Date of Patent: January 6, 2015Assignees: Centre National de la Recherche Scientifique, Les Hospices Civils de LyonInventors: Bruno Lina, Olivier Terrier, Danielle Françoise Thouvenot
-
Publication number: 20140370503Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.Type: ApplicationFiled: December 18, 2012Publication date: December 18, 2014Applicant: HOSPICES CIVILS DE LYONInventors: François Mallet, Nathalie Mugnier, Philippe Perot
-
Patent number: 8906386Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: December 9, 2014Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20140336368Abstract: A multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging.Type: ApplicationFiled: November 18, 2011Publication date: November 13, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, HOSPICES CIVILS DE LYONInventors: Delphine Felder-Flesch, Claire Billotey, Giuseppe Lamanna, Marc Janier, David Kriza
-
Publication number: 20140329261Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.Type: ApplicationFiled: December 17, 2012Publication date: November 6, 2014Applicants: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Alain Kfoury, Isabelle Coste-Invernizzi, Serge Lebecque, Toufic Renno
-
Patent number: 8778341Abstract: The invention relates to antibodies specific to human CK8 and to pharmaceutical compositions for preventing and treating colorectal cancers. The invention also relates to methods for identifying colorectal cancers with an invasive and/or metastatic phenotype including detecting the cleavage of the C-terminal portion of human CK8 on the surface of tumor cells.Type: GrantFiled: May 27, 2010Date of Patent: July 15, 2014Assignees: Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre National de la Recherche ScientifiqueInventors: Jean-Jacques Diaz, Jean-Xavier Roca-Martinez, Jean-Christophe Saurin, Serge Petit
-
Publication number: 20140038883Abstract: The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen atom or a non-substituted or substituted (C1-C6) alkyl group; R4 is a non-substituted or substituted (C1-C12) alkyl group or an aryl or heteroaryl group, said aryl and heteroaryl groups being non-substituted or substituted; and R5 is a non-substituted or substituted (C1-C12) alkyl group; or R4 and R5 are bonded to one another by a saturated hydrocarbon chain having 3 or 4 carbon atoms, optionally in hydrated form or in the form of a salt that is acceptable for being administered to animals or plants, for the use thereof as a potentiator of the effect of an antimicrobial agent or for the use thereof as an antimicrobial agent.Type: ApplicationFiled: January 27, 2012Publication date: February 6, 2014Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, HOSPICES CIVIL DE LYONInventors: Anne Doleans-Jordheim, Jean Freney, Charles Dumontet, Ahcene Boumend Jel, Jean-Baptiste Veron, Yung-Sing Wong
-
Patent number: 8623824Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.Type: GrantFiled: February 22, 2008Date of Patent: January 7, 2014Assignees: Biomethodes, Hospices Civils de LyonInventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
-
Publication number: 20130315954Abstract: The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.Type: ApplicationFiled: November 4, 2011Publication date: November 28, 2013Applicants: UNIVERSITY OF DUNDEE, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Olivier Terrier, Jean-Christophe Bourdon, Manuel Rosa-Calatrava
-
Publication number: 20130316930Abstract: The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.Type: ApplicationFiled: January 27, 2012Publication date: November 28, 2013Applicants: HOSPICES CIVILS DE LYON (HCL), BIOMERIEUXInventors: Fanny Davin, Alain Lepape, Guillaume Monneret, Florence Frager
-
Publication number: 20130210670Abstract: Method for determining a level of activity of a biological pathway from a biological sample of a patient suffering from a pathology, the method comprising the steps of: measuring the level of expression of at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is inactive, the at least three genes being associated to the biological pathway, for establishing a negative reference, and measuring level of expression of the at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is active, for establishing a positive reference, and measuring the level of expression of the at least three genes of the patient in the sample.Type: ApplicationFiled: September 19, 2011Publication date: August 15, 2013Applicants: Hospices Civils De Lyon, BiomerieuxInventors: Pierre Miossec, Bruno Mougin, Malick Paye, Frederic Reynier
-
Publication number: 20130183306Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.Type: ApplicationFiled: July 18, 2011Publication date: July 18, 2013Applicants: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Gilles Salles, Claudine Vermot-Desroches
-
Publication number: 20130115242Abstract: Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins.Type: ApplicationFiled: July 8, 2011Publication date: May 9, 2013Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), HOSPICES CIVILS DE LYONInventors: Vincent Moules, Manuel Rosa-Calatrava, Olivier Ferraris, Matthieu Yver
-
Patent number: 8419426Abstract: The invention relates to a positioning and immobilization device for positioning and immobilizing a mandibular or maxillary surgical guide on a patient, which guide is adapted to preparing for and to fitting at least one dental implant and is provided with a link slab member designed to extend outside the oral cavity when the surgical guide is placed in register with the patient's mandible or maxilla, said positioning and immobilization device being characterized in that it comprises a body that has bearing face for bearing against the outside of the head of the patient, and a fastener designed to co-operate with the link slab member of the surgical guide.Type: GrantFiled: July 22, 2008Date of Patent: April 16, 2013Assignee: Hospices Civils de LyonInventors: Marion Paris, Thomas Fortin
-
Publication number: 20130012502Abstract: Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.Type: ApplicationFiled: December 7, 2010Publication date: January 10, 2013Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Manuel Rosa-Calatrava, Jean-Jacques Diaz, Julien Textoris, Laurence Josset